Anglo-French Drugs & Industries Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.23 Cr
- Company Age 102 Year, 1 Day
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.81 Cr
- Satisfied Charges ₹ 68.40 Cr
- Revenue Growth -33.52%
- Profit Growth 13068.28%
- Ebitda -606.36%
- Net Worth 1032.45%
- Total Assets 183.17%
About Anglo-French Drugs & Industries
Anglo-French Drugs & Industries Limited (ADIL) was founded in India on 01 February 1923 and has a glorious history of 102 years . Its registered office is in Bangalore, Karnataka, India.
The Corporate was formerly known as The Anglo-French Drug Company (Eastern) Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.23 Cr.
The company currently has active open charges totaling ₹13.81 Cr. The company has closed loans amounting to ₹68.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Anglo-French Drugs & Industries Limited India are Sriee Aneetha as COMPANY SECRETARY and Nirbhay Kanoria as Cfo. Abhay Kanoria, Uddhav Kanoria, Ahmedali Nalagath, and Five other members serve as directors at the Company.
Company Details
-
Location
Bangalore, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
L24230KA1923PLC010205
-
Company No.
010205
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
01 Feb 1923
-
Date of AGM
03 Aug 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Listed
-
ROC Code
Roc Bangalore
Industry
What products or services does Anglo-French Drugs & Industries Limited offer?
Anglo-French Drugs & Industries Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Mineral Supplement, Vitamin Tablets & Capsules, Methylcobalamin Tablets, Iron Folic Acid Tablet, Diclofenac, Diclofenac Paracetamol Tablet, Pain Killers, Forte Tablets.
Who are the key members and board of directors at Anglo-French Drugs & Industries?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhay Kanoria
|
Managing Director | 01-Mar-1997 | Current |
|
Sriee Aneetha
|
Company Secretary | 16-Aug-2022 | Current |
| Nirbhay Kanoria | CFO | 29-Jan-2024 | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Uddhav Kanoria
|
Whole-Time Director | 10-Aug-2006 | Current |
|
Ahmedali Nalagath
|
Director | 24-Aug-2012 | Current |
|
Nirbhay Kanoria
|
Director | 01-Feb-2017 | Current |
|
Pradeep Joshi
|
Director | 11-Apr-2024 | Current |
|
Rohit Choraria
|
Director | 09-May-2023 | Current |
|
Rakesh Kanyadi
|
Director | 13-Aug-2019 | Current |
Financial Performance of Anglo-French Drugs & Industries.
Anglo-French Drugs & Industries Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 33.52% decrease. The company also saw a substantial improvement in profitability, with a 13068.28% increase in profit. The company's net worth Soared by an impressive increase of 1032.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anglo-French Drugs & Industries?
In 2022, Anglo-French Drugs & Industries had a promoter holding of 64.64% and a public holding of 35.36%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
H.R. Cornucopia Private LimitedAhmedali Nalagath is a mutual person
-
Radha Kesari Spinning Mills LimitedAbhay Kanoria and Uddhav Kanoria are mutual person
-
-
Ekta Tie-Up Private Limited
Abhay Kanoria and Nirbhay Kanoria are mutual person
-
Sudarshan Services Ltd
Abhay Kanoria is a mutual person
-
Shri Binod Kanoria Foundation
Abhay Kanoria and Nirbhay Kanoria are mutual person
Charges (Loans)
₹13.81 Cr
₹68.40 Cr
Charges Breakdown by Lending Institutions
- Yes Bank Limited : 13.70 Cr
- Axis Bank Limited : 0.11 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Sep 2019 | Axis Bank Limited | ₹1.12 M | Open |
| 07 Feb 2017 | Yes Bank Limited | ₹13.70 Cr | Open |
| 18 Jul 2021 | Hdfc Bank Limited | ₹7.00 M | Satisfied |
| 20 May 2021 | Yes Bank Limited | ₹1.20 Cr | Satisfied |
| 30 Oct 2015 | Srei Equipment Finance Limited | ₹1.00 Cr | Satisfied |
How Many Employees Work at Anglo-French Drugs & Industries?
Anglo-French Drugs & Industries has a workforce of 252 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anglo-French Drugs & Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anglo-French Drugs & Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
